NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Skin Immunity Sample Collection Involving Blisters and Biopsies

Early Phase 1

Withdrawn

Conditions: Hyper-Immunoglobulin E. Syndrome (HEIS)
Chronic Granulomatous Disease (CGD)

Interventions: Other: Blister induction
Other: Skin Biopsies

First Posted Date: 2019-04-19

Last Posted Date: 2024-12-13

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 70

Registration Number: NCT03921515

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali

Phase 2

Completed

Conditions: Malaria

Interventions: Biological: HAVRIX
Biological: Pfs230D1M-EPA/AS01
Biological: AVAXIM
Biological: TYPHIM Vi (Salmonella typhi vaccine)
Biological: Menactra

First Posted Date: 2019-04-17

Last Posted Date: 2024-10-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1301

Registration Number: NCT03917654

Locations: 🇲🇱
Mrtc/Usttb, Bamako, Mali

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Phase 1

Completed

Conditions: Respiratory Syncytial Virus (RSV)

Interventions: Biological: RSV ΔNS2/Δ1313/I1314L Vaccine
Biological: RSV 6120/ΔNS2/1030s Vaccine
Biological: RSV 276 Vaccine
Biological: Placebo

First Posted Date: 2019-04-16

Last Posted Date: 2024-05-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 67

Registration Number: NCT03916185

Locations: 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇺🇸
SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States
🇺🇸
Duke Vaccine and Trials Unit CRS, Durham, North Carolina, United States

and more 10 locations

Intravenous Fosfomycin Pharmacokinetics Study

Phase 1

Completed

Conditions: Multiple-drug Resistance
Pathogen Resistance
Bacterial Infection

Interventions: Drug: Fosfomycin disodium

First Posted Date: 2019-04-10

Last Posted Date: 2023-10-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 39

Registration Number: NCT03910673

Locations: 🇺🇸
Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States

Dried Blood Spot Testing of CMV Detection in HCT Recipients

Not Applicable

Completed

Conditions: Cytomegalovirus Infection

Interventions: Device: DBS Self-Collection Kit
Other: Standard Control Strategy

First Posted Date: 2019-04-10

Last Posted Date: 2024-10-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 622

Registration Number: NCT03910478

Locations: 🇺🇸
The University of Texas - MD Anderson Cancer Center - Infectious Diseases, Houston, Texas, United States
🇺🇸
Fred Hutchinson Cancer Research Center - Vaccine and Infectious Diseases, Seattle, Washington, United States
🇺🇸
University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States

and more 1 locations

Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

Early Phase 1

Recruiting

Conditions: Chronic Granulomatous Disease

Interventions: Drug: Busulfan
Drug: Alemtuzumab
Drug: Cyclophosphamide
Drug: Sirolimus
Radiation: Total Body Irradiation
Biological: Allogeneic peripheral blood stem cell

First Posted Date: 2019-04-10

Last Posted Date: 2024-10-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT03910452

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC)

Completed

Conditions: Coccidioidomycosis
Pneumonia

First Posted Date: 2019-04-09

Last Posted Date: 2024-01-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 651

Registration Number: NCT03908632

Locations: 🇺🇸
Kaiser Permanente Antelope Valley Medical Offices - Infectious Diseases, Lancaster, California, United States
🇺🇸
Kaiser Permanente Chester Avenue Medical Offices - Pulmonology, Bakersfield, California, United States
🇺🇸
Banner - University Medical Center Advanced Lung Disease Clinic - Phoenix, Phoenix, Arizona, United States

and more 3 locations

Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function

Phase 1

Recruiting

Conditions: Renal Impairment
Tuberculosis

Interventions: Drug: PA-824

First Posted Date: 2019-04-01

Last Posted Date: 2024-12-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT03896750

Locations: 🇺🇸
Alliance for Multispecialty Research, LLC - Knoxville, Knoxville, Tennessee, United States
🇺🇸
Advanced Pharma - Miami, Miami, Florida, United States
🇺🇸
Saint Louis University Center for Vaccine Development, Saint Louis, Missouri, United States

Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)

Conditions: Healthy Volunteer Samples

First Posted Date: 2019-03-29

Last Posted Date: 2025-01-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1000

Registration Number: NCT03895645

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Drug: Imatinib
Drug: Isoniazid
Drug: Rifabutin

First Posted Date: 2019-03-27

Last Posted Date: 2023-10-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT03891901

Locations: 🇺🇸
Emory University DAIDS TB Non-Network CRS, Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy